Venous Thromboembolism: Mechanisms, Treatment, and Public Awareness New Insights Into Cancer-Associated Thrombosis
نویسندگان
چکیده
Venous thromboembolism (VTE) is an increasingly frequent complication of anticancer therapy. The underlying mechanisms are not completely understood, but are related in part to oncogene activation and tissue factor (TF) expression. Several risk factors have been identified including site and stage of cancer, patient comorbidities, and specific therapeutic agents. Candidate biomarkers such as blood counts, TF, and P-selectin have recently been identified. A risk model predictive of chemotherapy-associated VTE has been validated. Thromboprophylaxis with low molecular weight heparin (LMWH), unfractionated heparin (UFH), or fondaparinux is recommended for hospitalized medical and surgical cancer patients. Long-term anticoagulation with LMWH is safe and effective in reducing recurrent VTE in cancer. The role of thromboprophylaxis in ambulatory cancer patients receiving chemotherapy is an area of active investigation. (Arterioscler Thromb Vasc Biol. 2009;29:316-320.)
منابع مشابه
Recurrent Venous Thromboembolism as the Initial Clinical Presentation of Gastric Cancer: A Case Report
Pulmonary thromboembolism (PTE) is a clinically critical disease, misdiagnosis or delayed diagnosis of which can lead to increased rate of mortality. For prevention of recurrence of PTE, recognition of its risk factors or underlying diseases is of great importance. PTE is common in patients with cancer and has high morbidity and mortality rates. Although cancer is a lethal condition, PTE accele...
متن کاملVenous Thromboembolism: Mechanisms, Treatment, and Public Awareness Venous Thromboembolism Risk Factors for Recurrence
Patients who have a first episode of venous thromboembolism (VTE) have an elevated risk of a recurrent episode, and this necessitates secondary prophylaxis. Anticoagulant therapy is a double-edged sword, however, as it reduces the risk of recurrent VTE but increases the risk of hemorrhage. This balance must be taken into account when assessing the risk-benefit ratio of long-term anticoagulation...
متن کاملA Rare Presentation of Arterial Thrombosis after Venous Thrombosis in a Patient with Gastric Cancer
Background: Venous thromboembolism, which comprises deep vein thrombosis and pulmonary embolism and is a significant cause of morbidity and mortality among patients with cancer. The aim of the present study was to report a rare presentation of arterial thrombosis after venous thrombosis in a patient with gastric cancer. Report of the Case: A 45 year-old female patient with locally advanced gas...
متن کاملVenous Thromboembolism: Mechanisms, Treatment, and Public Awareness
Patients who have a first episode of venous thromboembolism (VTE) have an elevated risk of a recurrent episode, and this necessitates secondary prophylaxis. Anticoagulant therapy is a double-edged sword, however, as it reduces the risk of recurrent VTE but increases the risk of hemorrhage. This balance must be taken into account when assessing the risk-benefit ratio of long-term anticoagulation...
متن کاملRivaroxaban versus enoxaparin for treatment of patients with nonhematologic cancer with venous thromboembolism a randomized clinial trial
Background: Low-Molecular-Weight Heparin (LMWH) is recommended as the first-line treatment in patients with active cancer and venous thromboembolism (VTE), but many patients prefer to take oral anticoagulants and non-injectable forms with more reasonable price. Venous thromboembolism is a very common comorbidity in patients with cancer. Therefore, the aim of this study was to evaluate the effic...
متن کامل